Am J Transplant, Volume 5, Suppl 3 Archives - Page 2 of 170 - ATC Abstracts

2015 American Transplant Congress
Post-Kidney Transplant Infections in Desensitized Patients Receiving Thymoglobulin or Daclizumab Induction: Results of a Randomized Clinical Trial
B. Orandi,¹ J. Locke,² E. Kraus,³ B. Lonze,¹ N. Desai,¹ N. Dagher,¹ N. Alachkar,³ C. Simpkins,⁴ F. Naqvi,³ D. Segev,¹ R. Montgomery,¹ R. Avery.³
¹Department of Surgery, Johns Hopkins University, Baltimore; ²Department of Surgery, University of Alabama--Birmingham, Birmingham; ³Department of Medicine, Johns Hopkins University, Baltimore; ⁴Department of Surgery, Dartmouth, Lebanon.
Live donor kidney transplant recipients requiring desensitization for donor-specific antibody, who were enrolled in a single-center randomized trial of thymoglobulin vs. daclizumab induction, were evaluated…
2015 American Transplant Congress
Loss of RIPK3 and Caspase-8 Enhance Intrinsic Apoptosis in Tubular Epithelial Cell (TEC) Death and Contributes to Kidney Ischemia Reperfusion Injury (IRI)
B. Sung,¹ Y. Su,³ A. Lau,³ J. Jiang,³ A. Haig,² D. Green,⁴ Z. Zhang,² A. Jevnikar.¹
¹Microbiology and Immunology, Western University, London, ON, Canada; ²Pathology, Western University, London, ON, Canada; ³Matthew Mailing Centre for Translational Transplant Studies, London Health Sciences Centre, London, ON, Canada; ⁴St. Jude Children's Research Hospital, Memphis, TN.
[Background] Ischemia-reperfusion injury (IRI), a complex limiting factor in organ transplant survival, is related to multiple death pathways. Eliminating the key necroptotic molecule (RIPK3) improves…
2015 American Transplant Congress
Outpatient Management of Delayed Graft Function (DGF) Is Associated With Reduced Length of Stay and Acute Rejection
B. Muth,¹ B. Astor,¹ J. Turk,¹ M. Mohamed,¹ S. Parajuli,¹ D. Kaufman,² D. Mandelbrot,¹ A. Djamali.^1,2
¹Department of Medicine, University of Wisconsin, Madison, WI; ²Department of Surgery, University of Wisconsin, Madison, WI.
Delayed graft function (DGF) increases hospital length of stay (LOS) and risk for readmission, rejection, early graft loss and death. We created a multidisciplinary DGF…
2015 American Transplant Congress
Safety and Efficacy of All Oral DAA Therapy for Genotype 1 HCV Post-Liver Transplant: Interval Results from the HCV-TARGET Multicenter Prospective Observational Study
J. O'Leary,¹ R. Brown,² K. Reddy,³ A. Kuo,⁴ G. Morelli,⁵ R. Stravitz,⁶ G. Everson,⁷ C. Durand,⁸ H. Vargas,⁹ P. Kwo,¹⁰ C. Frenette,¹¹ J. Peter,¹² M. Vainorius,¹² L. Akushevich,¹² D. Nelson,⁵ M. Fried,¹² N. Terrault.¹³
¹Baylor University Medical Center, TX; ²Columbia University, NY; ³University of Pennsylvania, PA; ⁴UCSD, CA; ⁵University of Florida, Gainesville, Gainesville, FL; ⁶Virginia Commonwealth University, VA; ⁷University of Colorado, CO; ⁸Johns Hopkins, MD; ⁹Mayo Clinic, AZ; ¹⁰Indiana University, IL; ¹¹Scipps Clinic, CA; ¹²University of North Carolina, NC; ¹³UCSF, CA.
The safety and efficacy of direct-acting antivirals (DAA) for HCV post-LT remain unknown. METHODS: We describe the safety and efficacy of all oral DAA-therapy for…
2015 American Transplant Congress
Six Year Follow-Up of a Phase 2 Clinical Trial to Induce Tolerance in Mismatched Living Donor Renal Transplant Recipients
J. Leventhal, M. Abecassis, L. Gallon, J. Galvin, J. Mehta, K. Ravindra, D. Tollerud, M. Elliott, S. Ildstad.
Comprehensive Transplant Center, Northwestern Memorial Hospital, Chicago, IL; Duke University, Durham, NC; Institute for Cellular Therapeutics, University of Louisville, Louisville, KY; Regenerex, LLC, Louisville, KY.
27 subjects have been transplanted in a phase 2 protocol (IDE 13947) based upon tolerogenic CD8+/TCR- facilitating cells (FCRx) and 200 cGy TBI-based nonmyeloablative conditioning…
2015 American Transplant Congress
Hepatic Stellate Cells Directly Inhibit B Cells Via PD-L1
Y. Li, K. Fang, S. Qian, J. Fung, L. Lu, F. Lin.
Immunology, Lerner Research Institute; 2General Surgery, Digestive Disease Institute, Cleveland Clinic, Cleveland, OH.
Hepatic stellate cells (HSCs) account for one third of the nonparenchymal cells in the liver, which are considered to be critical in maintaining the immunoprivileged…
2015 American Transplant Congress
Functional Status Predicts Mortality After Liver Transplant
N. Dolgin,^1,2 P. Martins,¹ F. Anderson,^1,2 A. Bozorgzadeh.¹
¹Surgery, UMass Memorial Medical Center, Worcester, MA; ²Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, MA.
Purpose: To investigate whether pre-transplant functional status predicts mortality after liver transplant (LT).Methods: We conducted a retrospective cohort study of first-time adult LT recipients using…
2015 American Transplant Congress
Induction Therapy Improves 15-Year Graft Survival in Kidney Transplant Recipients With Acute Rejection
R. Bajoka, M. Goggins, A. Patel.
Transplant Institute, Henry Ford Hospital, Detroit, MI.
Background: Graft(GS) and patient survival(PS) has been shown to be superior in patients without delayed graft function (DGF) or acute rejection(AR). Induction therapy(IT) is frequently…
2015 American Transplant Congress
Impact of Cold Ischemic Time (CIT) and Distance Traveled (DT) on Shipped Kidneys in the OPTN/UNOS Kidney Paired Donation (KPD) Pilot Program (PP)
M. Aeder,¹ D. Stewart,² R. Leishman,² L. Robbins Callahan,² A. Kucheryavaya,² T. Sandholm,³ R. Formica.⁴
¹Univ Hosp Case Med Ctr, Cleveland, OH; ²UNOS, Richmond, VA; ³Carnegie Mellon Univ, Pittsburgh, PA; ⁴Yale Univ, New Haven, CT.
Background: The success of a national KPD program is predicated on excellent early kidney function and graft survival (GS). As other KPD programs have reported…
2015 American Transplant Congress
Adoptive Immunotherapy With Liver Allograft-Derived NK Cells Improves Recurrence-Free Survival After Living-Donor Liver Transplantation in Patients With Hepatocellular Carcinoma
N. Tanimine, Y. Tanaka, K. Ishiyama, M. Ohira, S. Shimizu, T. Yano, H. Ohdan.
Department of Gastroenterological and Transplant Surgery, Hiroshima University, Hiroshima, Japan.
Introduction: Previous studies revealed that the recurrence rate of hepatocellular carcinoma (HCC) was still 10–20%, even among liver transplantation (LT) recipients meeting the Milan criteria…